Cancer-associated HIF-2α impacts trunk neural crest stemness
Abstract
The neural crest is a stem cell population that gives rise to sympathetic ganglia, the cell type of origin of neuroblastoma. Hypoxia Inducible Factor (HIF)-2α is associated with high risk neuroblastoma, however, little is known about its role in normal neural crest development. To address this important question, here we show that HIF-2α is expressed in trunk neural crest cells of human, murine and avian embryos. Modulating HIF-2α in vivo not only causes developmental delays but also induces proliferation and stemness of neural crest cells while altering the number of cells migrating ventrally to sympathoadrenal sites. Transcriptome changes after loss of HIF-2α reflect the in vivo phenotype. The results suggest that expression levels of HIF-2α must be strictly controlled and abnormal levels increase stemness and may promote metastasis. Our findings help elucidate the role of HIF-2α during normal development with implications also in tumor initiation at the onset of neuroblastoma.
Additional Information
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. bioRxiv preprint first posted online Jan. 23, 2020. We would like to thank Erica Hutchins, Shashank Gandhi and Siv Beckman for skillful technical assistance and Anni Glud and Ronnie N. Glud for providing microsensor technique and expertise. This work was supported by the Swedish Cancer Society, the Swedish Childhood Cancer Fund, the Craaford Foundation, Jeansson Foundations, Ollie and Elof Ericsson's foundation, the Mary Bevé Foundation, Magnus Bergvall's foundation, the Thelma Zoega foundation for medical research, Hans von Kantzow's foundation, the Royal Physiographic Society of Lund, the Gyllenstierna Krapperup's Foundation, and Gunnar Nilssons Cancerstiftelse (to SM), DE027568 and R01HL14058 (to MEB). We thank Center for Translational Genomics, Lund University and Clinical Genomics Lund, SciLifeLab for providing sequencing service. Support by NBIS (National Bioinformatics Infrastructure Sweden) is gratefully acknowledged. Author contributions: SM, CUP, EF and EH performed experiments. SM, EH and MEB analyzed data. SM and JML analyzed RNA sequencing data. EM and ZK provided materials. SM and MEB supervised the study. SM wrote the original draft of the manuscript while all authors reviewed and edited the manuscript. The authors declare no competing interests.Attached Files
Submitted - 2020.01.22.915199v1.full.pdf
Files
Name | Size | Download all |
---|---|---|
md5:02ebc2b60b916d4cde4ee9072bb4388c
|
13.4 MB | Preview Download |
Additional details
- Eprint ID
- 100869
- Resolver ID
- CaltechAUTHORS:20200123-094934019
- Swedish Cancer Society
- Swedish Childhood Cancer Fund
- Craaford Foundation
- Jeansson Foundations
- Ollie and Elof Ericssons Foundation
- Mary Bevé Foundation
- Magnus Bergvall Foundation
- Thelma Zoéga Foundation
- Hans von Kantzow's Foundation
- Royal Physiographic Society of Lund
- Gyllenstierna Krapperup's Foundation
- Gunnar Nilsson Cancer Foundation
- NIH
- DE027568
- NIH
- R01HL14058
- National Bioinformatics Infrastructure Sweden
- Created
-
2020-01-23Created from EPrint's datestamp field
- Updated
-
2021-11-16Created from EPrint's last_modified field
- Caltech groups
- Division of Biology and Biological Engineering